Abstract Objective To investigate the screening indices and their cut-off values for full-term neonates carrying β-thalassemia gene.Methods A retrospective analysis was performed for the clinical data of 1 193 full-term neonates who underwent β-thalassemia screening (hemoglobin analysis with dried blood spots on neonatal heel blood filter paper and mutation detection of 17 β-globin genes). A multivariate logistic regression analysis was used to investigate the association between screening indices and β-thalassemia gene, and the receiver operating characteristic (ROC) curve was used to analyze the value of screening indices in determining the presence or absence of β-thalassemia gene.Results Of the 1 193 neonates, 638 carried β-thalassemia gene. Of the 1 193 neonates, 637 (53.39%) had no HbA2, among whom 310 carried β-thalassemia gene and 327 did not carry this gene; 556 (46.61%) had HbA2, among whom 328 carried β-thalassemia gene and 228 did not carry this gene. As for the neonates without HbA2, the β-thalassemia gene group had a significantly lower HbA level and a significantly higher HbF level than the β-thalassemia gene-negative group (P < 0.01). As for the neonates with HbA2, the β-thalassemia gene group had a significantly lower HbA level and significantly higher HbF and HbA2/HbA ratio than the β-thalassemia gene-negative group (P < 0.01). In the neonates without HbA2, HbA, gestational age, and HbA combined with gestational age had an area under the ROC curve (AUC) of 0.865, 0.515, and 0.870, respectively, in determining the presence or absence of β-thalassemia gene (P < 0.01), and HbA and HbA combined with gestational age had a similar AUC and a certain diagnostic value. In the neonates with HbA2, HbA, HbA2/HbA ratio, and HbA combined with HbA2/HbA ratio had an AUC of 0.943, 0.885, and 0.978, respectively, in determining the presence or absence of β-thalassemia gene. The HbA combined with HbA2/HbA ratio had the largest AUC. In the neonates without HbA2, HbA had the largest AUC in determining the presence or absence of β-thalassemia gene at the cut-off value of 11.6%, with a sensitivity of 85.81% and a specificity of 79.82%. In the neonates with HbA2, an HbA of 16.1%-22.0% and an HbA2/HbA ratio of > 1.4 had the largest AUC in determining the presence or absence of β-thalassemia gene, with a sensitivity of 91.38% and a specificity of 91.89%.Conclusions HbA and HbA2/HbA ratio are effective indices for screening out full-term neonates carrying β-thalassemia gene.
YANG Jin-Ling,CAI Ren,CHEN Da-Yu et al. Screening indices and their cut-off values for full-term neonates carrying β-thalassemia gene[J]. CJCP, 2018, 20(12): 990-993.
YANG Jin-Ling,CAI Ren,CHEN Da-Yu et al. Screening indices and their cut-off values for full-term neonates carrying β-thalassemia gene[J]. CJCP, 2018, 20(12): 990-993.
Xu XM, Zhou YQ, Luo GX, et al. The prevalence and spectrum of α and β thalassaemia in Guangdong province:implications for the future health burden and population screening[J]. J Clin Pathol, 2004, 57(5):517-522.
Mantikou E, Arkesteijn SG, Beckhoven van JM, et al. A brief review onnewborn screening methods for hemoglobinopathies and preliminary results selecting beta thalassemia carriers at birth by quantitative estimation of the HbA fraction[J]. Clin Biochem, 2009, 42(8):1780-1785.
Kubikova N, Babariya D, Sarasa J, et al. Clinical application of a protocol based on universal next-generation sequencing for the diagnosis of beta-thalassaemia and sickle cell anaemia in preimplantation embryos[J]. Reprod Biomed Online, 2018, 37(2):136-144.
Giordano PC. Newborn screening for hemoglobinopathies using capillary electrophoresis[J]. Methods Mol Biol, 2013, 919:131-145.
[13]
Mantikou E, Harteveld CL, Giordano PC. Newborn screening for hemoglobinopathies using capillary electrophresis technology:Testing the capillarys neonat fast Hb device[J]. Clin Biochem, 2010, 43(16-17):1345-1350.
